Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:35:47.085Z.
Consensus retrieved: 2026-10-06T09:08:06.929Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:35:47.085Z.
Quote observation: 2026-10-06T16:35:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8a640fc23e826184f41bff562ebaec2cbd698d76cf0575ea0d93a5fb3bafa380
Forward PE Ratio (N/A) = Dated Quote Price ($55.01) / Consensus Forward EPS ($0.11)
FORWARD PE RATIO
N/A
AtriCure, Inc.
Market Cap
$2.80B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| AtriCure, Inc. (ATRC) | $2.80B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.80B | 55.20 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.87B | N/A |
| Precigen, Inc. (PGEN)vs › | $2.73B | 44.67 |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | 18.99 |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.69B | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 14.98 |
| Neogen Corporation (NEOG)vs › | $2.68B | 39.61 |
| Beam Therapeutics Inc. (BEAM)vs › | $2.59B | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.59B | N/A |
Trailing P/E
259.2
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.11 implies -47.6% EPS decline vs the reported trailing $0.21.
At the dated quote price of $55.01, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.11 | $0.10 – $0.11 | 6 | 514.4x |
| 2027-12-31 | $0.42 | $0.37 – $0.47 | 7 | 131.4x |
| 2028-12-31 | $0.70 | $0.41 – $1.02 | 7 | 79.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
